Champion the New Era of Medicine

Make targeted medicine a reality

IRIS Wellness Labs (IRIS) is a subsidiary of IRIS Biotechnologies (IRSB) Inc. IRIS tests DNA, microbial function, and chemical signatures of metabolites. IRIS examines up to 3.2 billion molecules in a person’s DNA sequence, about 10 million microbial gene activities, and approximately 900 metabolites. But that’s only the beginning. IRIS then integrates this information with personal medical records, lifestyle, family history and environmental factors. Knowing how to interpret this information is more important than the information itself.

The IRIS approach is based on more than 20 years of research and program development in obtaining accurate data, and learning how to meaningfully integrate it into health management. The IRIS platform itself is continually updated with new scientific data and its management.

IRIS makes it easy for Employers to save significant money, improve productivity, and have a healthier workforce. IRIS works with individual employees and their doctors as needed. The depth of analysis by IRIS provides health care professionals with quicker, deeper insights into the nature of specific pathologies, enabling quicker, and more effective therapeutic interventions.

IRIS Wellness Labs is privately held, but has the potential to be listed on major stock exchanges such as the NASDAQ. If you would like more information or would like to invest, send an e-mail to simonchin@iriswellnesslabs.com.

Iris BioTechnologies Inc. (IRSB) is a publicly traded life sciences company with patented technologies providing one of the most comprehensive analysis to you and your physicians with the information to choose the best medical treatment regimen before the treatment begins. IRSB enables precision healthcare, the future of medicine.

IRSB is confident that we offer the best approach to enable physicians to treat diseases such as cancer through actionable integration of molecular profiling with clinical decision making, precision analysis of potential cancer recurrence and therapeutic effectiveness, along with matching to targeted therapies and therapies in clinical trials.

If you would like more information or would like to invest, send an e-mail to simonchin@irisbiotech.com.